News

Under the terms of the license agreement, BioWa grants KaloBios non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through Potelligent technology for an undisclosed number of

According to the agreement, Laureate will produce Tolera’s TOL101 monoclonal antibody under current good manufacturing practice (cGMP) conditions to be used in clinical trials. John Puisis, president and

Under the terms of the agreement, Exiqon obtains from Roche a non-exclusive license to use SYBR Green I in real time polymerase chain reaction (PCR). SYBR Green provides

Ikonisys said that oncoFISH her2 is a fully automated microscopy application for the determination of HER2 status in human breast cancer specimens processed with Abbott’s PathVysion HER2 DNA

Together, these licenses from the regulatory bodies ensure this facility is ready to support the supply of Bayer’s Kogenate FS/ Kogenate Bayer (antihemophilic factor [recombinant]) line of products

The Phase II trial compared the efficacy and safety of five days of therapy with either 200mg intravenous (IV) peramivir per day, 400mg IV peramivir per day or

In the preclinical study, C-20081 had a 43% increase in plasma half-life compared to linezolid, which might allow for lower overall drug exposure and improved tolerability with a

The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to

The Phase Ib clinical trial is a double-blind, placebo-controlled study that will evaluate the tolerability, pharmacokinetics and viral kinetics of multiple, ascending doses of ANA598 over a period